Fig. 3.

Longitudinal analysis of biomarkers of neurodegeneration in lumbar (A, C, E, G, and I) and ventricular (B, D, F, H, and J) CSF for amyloid-β₄₂ (Aβ₄₂; A, B), total tau (T-tau; C, D), tau phosphorylated at threonine 181 (P-tau; E, F), neurofilament light (NFL; G, H), and neurogranin (NRGN; I, J). iNPH patients were grouped into to biopsy positive (dark gray) and biopsy negative (light gray) patients based on the presence or absence of Aβ pathology in their corresponding frontal biopsy. Values expressed as means±standard error. ^*p < 0.05; ^**p < 0.01 between biopsy-positive and -negative patients in specific time point. B1, pre-surgery sample collection time point; B0, baseline visit of the follow-up; 3 M, three-month study visit; 6 M, six-month study visit; 18 M, 18-month study visit; L-CSF, cerebrospinal fluid collected with lumbar puncture; V-CSF, cerebrospinal fluid collected with shunt valve puncture.